Investor Alert: Lexaria Bioscience - The Modern Way to Improve Oral Drugs

September 7, 2021

Demonstrated Early-Stage Effectiveness

Lexaria Bioscience began developing DehydraTECH in 2014. Since then, they have strengthened and broadened the technology to an unprecedented degree. They are a global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs.


DehydraTECH is one of the world's newest technologies designed to improve the efficacy of orally administered bioactive molecules. That includes; anti-viral drugs, nicotine, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, and other molecules.

Additionally, DehydraTECH increases bio-absorption by up to 5x, reduces the time of onset from up to 1 – 2 hours to just minutes, masks unwanted tastes, and can reduce unwanted side effects by enabling lower overall dosing.

For more information on Lexaria Bioscience (NASDAQ: LEXX) please click the request investor info button.

You might also like

Brompton Funds: Global Healthcare Income & Growth ETF

Global Healthcare Management is active management and distributions program. It will gain knowledge of the established and emerging concept.

CEO Clips - Unicycive Therapeutics: Innovation to Improve Quality of Life For Patients Suffering from Kidney Diseases

Developing life-changing new medicines to treat a variety of kidney diseases with significant unmet medical needs.

Content Broadcast on: BNN Bloomberg, Bloomberg, FOX Business News, BIZTV, Reuters, YouTube and more!